课题基金 / 基金详情

A Novel Pharmacotherapy for Alcoholism: Evaluation of Reward, Aversion, Compulsivity, Withdrawal & Reinstatement

A Novel Pharmacotherapy for Alcoholism: Evaluation of Reward, Aversion, Compulsivity, Withdrawal & Reinstatement
一种治疗酒精中毒的新型药物疗法:奖励、厌恶、强迫、戒断的评估
批准号:
10523383
负责人:
ABRAHAM A PALMER
金额:
$8.97万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-05 至 2023-04-30

项目摘要

项目成果

ABRAHAM A PALMER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project summary Alcohol use disorder (AUD) is an extremely common and serious condition that is associated with numerous somatic diseases, early mortality, personal and interpersonal hardship, and direct and indirect economic costs to society. Although there are several effective pharmacological treatments for AUD, their limited effectiveness contributes to the ongoing burden of AUD on society. A major impediment to better treatments for AUD is the lack of understanding surrounding fundamental molecular mechanisms associated with alcohol’s acute and chronic effects on the brain. Ongoing work in our lab has demonstrated that genetic and pharmacological manipulation of the enzyme Glyoxalase 1 (GLO1) can reduce ethanol drinking in mice and rats. GLO1 is an evolutionarily conserved enzyme that metabolizes methylglyoxal (MG), which is a non- enzymatic side product of glycolysis and is thus present in all animal cells. Transgenic overexpression of GLO1 decreases MG (GLO1’s substrate) in the brain. Reciprocally, direct administration of MG, genetic knockdown of Glo1 or pharmacological inhibition of GLO1 increase MG concentrations in the brain. We showed that MG is a selective agonist at GABA-A receptors. More recently, we discovered that GLO1 and MG modulate ethanol drinking behavior, which we hypothesize is due to MG’s effects at GABA-A receptors. In this supplement request, we are extending on the studies funded by the parent R01 to pursue a new line of experimentation. Specifically, we are exploring the possibility that ethanol may be directly converted into MG on a timescale that is consistent with the acute effects of ethanol. This exciting possibility raises the tantalizing possibility that some of ethanol’s effects on GABA-A receptors could be due to MG (rather than ethanol), directly influencing GABA-A signaling. We will test this possibility by measuring MG levels at various time points following administration of ethanol. In subsequent experiments, we will explore the possibility that ethanol is directly converted into MG (as opposed to altering MG in an indirect manner) by administering stable-labeled ethanol in which the hydrogen atoms have been replaced with deuterium. We will use mass- spec to assess MG levels, which will allow us to distinguish unlabeled MG from MG labeled with one or more deuterium atoms. These studies have the potential to greatly enhance our mechanistic understanding of ethanol’s actions. The mentoring plan is also described; the primary goal is to prepare the trainee to enter a Ph.D. program.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Assessing the motivational effects of ethanol in mice using a discrete-trial current-intensity intracranial self-stimulation procedure.
使用离散试验电流强度颅内自刺激程序评估乙醇对小鼠的激励作用。
DOI: 10.1016/j.drugalcdep.2019.107806
发表时间: 2020
期刊: Drug and alcohol dependence
影响因子: 4.2
作者: [Barkley-Levenson,AmandaM, Der-Avakian,Andre, Palmer,AbrahamA]
通讯作者: Palmer,AbrahamA
DOI: 10.3390/brainsci11010127
发表时间: 2021-01-19
期刊: Brain sciences
影响因子: 3.3
作者: [Barkley-Levenson AM, Lee A, Palmer AA]
通讯作者: Palmer AA
DOI: 10.1038/s41593-020-0609-7
发表时间: 2020-04
期刊: NATURE NEUROSCIENCE
影响因子: 25
作者: [Sanchez-Roige, Sandra, Palmer, Abraham A.]
通讯作者: Palmer, Abraham A.
A Novel Pharmacotherapy for Alcoholism: Evaluation of Reward, Aversion, Compulsivity, Withdrawal & Reinstatement
A Novel Pharmacotherapy for Alcoholism: Evaluation of Reward, Aversion, Compulsivity, Withdrawal & Reinstatement
A Novel Pharmacotherapy for Alcoholism: Evaluation of Reward, Aversion, Compulsivity, Withdrawal & Reinstatement
Systems Genetic Analysis of Methamphetamine's Motivational Effects in a Mouse AIL
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: